Murray Grossman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5959643/publications.pdf Version: 2024-02-01

		7561	4770
295	32,324	77	169
papers	citations	h-index	g-index
315	315	315	23485
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
2	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	3.7	38
3	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
4	Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology. NeuroImage: Clinical, 2022, 33, 102913.	1.4	17
5	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	3.9	12
6	Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 517-526.	1.1	13
7	Divergent Histopathological Networks of Frontotemporal Degeneration Proteinopathy Subytpes. Journal of Neuroscience, 2022, 42, 3868-3877.	1.7	4
8	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration, 2022, 17, 29.	4.4	7
9	Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology. Neurobiology of Aging, 2022, 113, 95-107.	1.5	5
10	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
11	Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology. Neurology, 2022, 99, .	1.5	17
12	Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting. Npj Parkinson's Disease, 2022, 8, .	2.5	13
13	Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2022, 88, 1553-1566.	1.2	2
14	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
15	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, 822-830.	0.4	27
16	Cross-sectional and longitudinal medial temporal lobe subregional atrophy patterns in semantic variant primary progressive aphasia. Neurobiology of Aging, 2021, 98, 231-241.	1.5	5
17	Lexical and Acoustic Characteristics of Young and Older Healthy Adults. Journal of Speech, Language, and Hearing Research, 2021, 64, 302-314.	0.7	10
18	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. Neurology, 2021, 96, e1755-e1760.	1.5	1

#	Article	IF	CITATIONS
19	Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology. Acta Neuropathologica Communications, 2021, 9, 30.	2.4	22
20	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiology of Aging, 2021, 103, 158.e1-158.e5.	1.5	8
21	Lessons learned from a progressive supranuclear palsy trial. Lancet Neurology, The, 2021, 20, 162-163.	4.9	2
22	Automated analysis of lexical features in frontotemporal degeneration. Cortex, 2021, 137, 215-231.	1.1	18
23	Tau immunotherapy is associated with glial responses in FTLD-tau. Acta Neuropathologica, 2021, 142, 243-257.	3.9	22
24	Digital Speech Analysis in Progressive Supranuclear Palsy and Corticobasal Syndromes. Journal of Alzheimer's Disease, 2021, 82, 33-45.	1.2	12
25	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
26	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. Acta Neuropathologica, 2021, 142, 629-642.	3.9	15
27	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. Brain, 2021, 144, 2784-2797.	3.7	38
28	Automated Analysis of Digitized Letter Fluency Data. Frontiers in Psychology, 2021, 12, 654214.	1.1	5
29	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Movement Disorders, 2021, 36, 2945-2950.	2.2	63
30	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
31	Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration. Neurobiology of Aging, 2021, 108, 16-23.	1.5	2
32	Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias. Neurology, 2021, 96, e1855-e1864.	1.5	28
33	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. Acta Neuropathologica Communications, 2021, 9, 173.	2.4	14
34	Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies. Biomolecules, 2021, 11, 1484.	1.8	3
35	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	3.3	13
36	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5

#	Article	IF	CITATIONS
37	Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau. Acta Neuropathologica Communications, 2021, 9, 184.	2.4	2
38	Automatic analysis and validation of digitized speech markers in Lewy body spectrum diseases with Alzheimer's disease coâ€pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
39	Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, e052495.	0.4	Ο
40	Cerebrospinal fluid neurogranin in nonâ€amnestic and amnestic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
41	Automatic classification of AD versus FTLD pathology using speech analysis in a biologically confirmed cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	2
42	Calsynteninâ€1 is a cerebrospinal fluid marker of frontotemporal dementiaâ€related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.4	1
43	Reduced longitudinal change in ¹⁸ Fâ€flortaucipir PET is associated with clinical phenotype in atypical Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
44	Application of histopathologically derived 3D tau burden map as inâ€vivo region of interest for biomarker analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
45	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	1
46	A novel antibodyâ€free mass spectrometry panel of CSF biomarkers for synaptic dysfunction. Alzheimer's and Dementia, 2021, 17, .	0.4	1
47	Regional distribution of tau pathology in subfields of hippocampus among phenotypic variants of AD and FTLD-tau Alzheimer's and Dementia, 2021, 17 Suppl 3, e052392.	0.4	0
48	Mapping tau burden and neuronal loss in MAPT-associated frontotemporal lobar degeneration Alzheimer's and Dementia, 2021, 17 Suppl 3, e054141.	0.4	0
49	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
50	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	2.2	37
51	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
52	Characterization of hippocampal subfields using ex vivo MRI and histology data: Lessons for in vivo segmentation. Hippocampus, 2020, 30, 545-564.	0.9	31
53	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.4	45
54	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175

#	Article	IF	CITATIONS
55	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
56	Autosomal dominant VCP hypomorph mutation impairs disaggregation of PHF-tau. Science, 2020, 370, .	6.0	85
57	ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. Brain, 2020, 143, 2295-2311.	3.7	24
58	Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders. Neurology, 2020, 95, e1629-e1639.	1.5	19
59	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. Annals of Clinical and Translational Neurology, 2020, 7, 2342-2355.	1.7	20
60	Clinical Conditions "Suggestive of Progressive Supranuclear Palsyâ€â€"Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	2.2	22
61	Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. Acta Neuropathologica, 2020, 140, 675-693.	3.9	15
62	The Neural Basis of Metaphor Comprehension: Evidence from Left Hemisphere Degeneration. Neurobiology of Language (Cambridge, Mass), 2020, 1, 474-491.	1.7	5
63	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19
64	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	3.9	210
65	Comparison of the Iowa Reference Algorithm to the Heidelberg Spectralis optical coherence tomography segmentation algorithm. Journal of Biophotonics, 2020, 13, e201960187.	1.1	3
66	Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 843-852.	0.4	43
67	So Many Are "Few,―but so Few Are Also "Few―– Reduced Semantic Flexibility in bvFTD Patients. Frontiers in Psychology, 2020, 11, 582.	1.1	4
68	More Than Words: Extra-Sylvian Neuroanatomic Networks Support Indirect Speech Act Comprehension and Discourse in Behavioral Variant Frontotemporal Dementia. Frontiers in Human Neuroscience, 2020, 14, 598131.	1.0	4
69	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. Journal of Neuropathology and Experimental Neurology, 2020, 79, 296-304.	0.9	35
70	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
71	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	2.8	88

72 LATE to the PART-y. Brain, 2019, 142, e47-e47.

3.7 44

#	Article	IF	CITATIONS
73	Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration. Frontiers in Neuroscience, 2019, 13, 682.	1.4	13
74	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. Radiology, 2019, 293, 646-653.	3.6	20
75	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
76	Genetic predictors of survival in behavioral variant frontotemporal degeneration. Neurology, 2019, 93, e1707-e1714.	1.5	11
77	Validated automatic speech biomarkers in primary progressive aphasia. Annals of Clinical and Translational Neurology, 2019, 6, 4-14.	1.7	45
78	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
79	Clinical Correlates of Alzheimer's Disease Cerebrospinal Fluid Analytes in Primary Progressive Aphasia. Frontiers in Neurology, 2019, 10, 485.	1.1	5
80	A longitudinal study of speech production in primary progressive aphasia and behavioral variant frontotemporal dementia. Brain and Language, 2019, 194, 46-57.	0.8	34
81	Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease. Brain, 2019, 142, 1701-1722.	3.7	37
82	Persistent and Progressive Outer Retina Thinning in Frontotemporal Degeneration. Frontiers in Neuroscience, 2019, 13, 298.	1.4	17
83	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	2.2	93
84	Divergent patterns of TDPâ€43 and tau pathologies in primary progressive aphasia. Annals of Neurology, 2019, 85, 630-643.	2.8	40
85	<i>TMEM106B</i> Effect on cognition in Parkinson disease and frontotemporal dementia. Annals of Neurology, 2019, 85, 801-811.	2.8	52
86	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
87	O4â€03â€01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA. Alzheimer's and Dementia, 2019, 15, P1234.	0.4	0
88	ICâ€₽â€143: RELATIVE SPARING OF MEDIAL TEMPORAL SUBREGION VOLUMES IN NONâ€AMNESTIC ALZHEIMER DISEASE. Alzheimer's and Dementia, 2019, 15, P116.	.'S _{0.4}	0
89	O4â€02â€01: PHASE 2A RANDOMIZED, DOUBLEâ€BLIND, PLACEBOâ€CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRMâ€0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS. Alzheimer's and Dementia. 2019, 15, P1231.	0.4	4
90	ICâ€Pâ€043: CONTRIBUTION OF TAU, TDPâ€43, βâ€AMYLOID AND αâ€SYNUCLEIN TO MEDIAL TEMPORAL LOB Alzheimer's and Dementia, 2019, 15, P46.	E ATROPH	Y. ₀

Murray Grossman

#	Article	IF	CITATIONS
91	Amyotrophic lateral sclerosis — a multisystem neurodegenerative disorder. Nature Reviews Neurology, 2019, 15, 5-6.	4.9	18
92	Elevated CSF GAPâ€43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
93	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	15.2	111
94	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
95	Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 180-186.	0.9	17
96	UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2019, 73, 190-199.	1.5	31
97	Occupational attainment influences longitudinal decline in behavioral variant frontotemporal degeneration. Brain Imaging and Behavior, 2019, 13, 293-301.	1.1	18
98	Cognitive and Neuroanatomic Accounts of Referential Communication in Focal Dementia. ENeuro, 2019, 6, ENEURO.0488-18.2019.	0.9	3
99	CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology, 2018, 90, e1038-e1046.	1.5	68
100	Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. Brain, 2018, 141, 288-301.	3.7	56
101	Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies. Neurobiology of Aging, 2018, 68, 85-92.	1.5	11
102	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
103	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
104	Cerebrospinal fluid αâ€synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1052-1062.	0.4	34
105	Characterizing the human hippocampus in aging and Alzheimer's disease using a computational atlas derived from ex vivo MRI and histology. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4252-4257.	3.3	136
106	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	4.5	54
107	Tauopathy with hippocampal 4â€repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathology, 2018, 28, 274-283.	2.1	12
108	¹⁸ F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease. Journal of Nuclear Medicine, 2018, 59, 299-306.	2.8	48

#	Article	IF	CITATIONS
109	Production of verbs related to body movement in amyotrophic lateral sclerosis (ALS) and Parkinson's Disease (PD). Cortex, 2018, 100, 127-139.	1.1	16
110	Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiology of Aging, 2018, 63, 75-87.	1.5	61
111	Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Human Brain Mapping, 2018, 39, 691-708.	1.9	59
112	Linguistic Aspects of Primary Progressive Aphasia. Annual Review of Linguistics, 2018, 4, 377-403.	1.2	39
113	P1â€433: GRAY MATTER DEFICITS IN SYMPTOMATIC AND PRESYMPTOMATIC <i>MAPT</i> MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.4	0
114	O2â€14â€06: DIFFERENCES BETWEEN SPORADIC AND FAMILIAL BEHAVIORAL VARIANT FTD IN ADVANCING RESEARCH AND TREATMENT FOR FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM. Alzheimer's and Dementia, 2018, 14, P658.	0.4	0
115	ICâ€06â€03: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NONâ€AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P12.	0.4	0
116	P3â€565: RISK FACTORS FOR CLINICAL AD IN U.S. LATINO POPULATIONS: AN ANALYSIS OF THE NACC DATABASE Alzheimer's and Dementia, 2018, 14, P1340.	0.4	0
117	P1â€281: NONLINEAR Nâ€SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER'S COORDINATING CENTER (NACC) DATASET. Alzheimer's and Dementia, 2018, 14, P390.	0.4	1
118	O2â€14â€02: THE CLINICAL SPECTRUM OF FRONTOTEMPORAL LOBAR DEGENERATION IN NORTH AMERICA: BASELINE CHARACTERISTICS OF THE FIRST 912 PARTICIPANTS FROM THE ADVANCING RESEARCH AND TREATMENT IN FTLD (ARTFL) CLINICAL RESEARCH CONSORTIUM. Alzheimer's and Dementia, 2018, 14, P656.	0.4	0
119	O1â€08â€01: THE NIHâ€EXAMINER IS SENSITIVE TO COGNITIVE CHANGES IN ASYMPTOMATIC AND MILDLY SYMPTOMATIC FAMILIAL FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P235.	0.4	0
120	P1â€419: USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P465.	0.4	0
121	P3â€406: DISTINCT LONGITUDINAL CORTICAL ATROPHY IN NONâ€AMNESTIC COMPARED TO AMNESTIC ALZHEIMER'S DISEASE SUGGESTS DIFFERENT PATTERNS OF SPREADING PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1259.	0.4	0
122	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
123	Converging Patterns of α-Synuclein Pathology in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1005-1016.	0.9	26
124	Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. Neurolmage: Clinical, 2018, 19, 497-506.	1.4	21
125	Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2018, 61, 1691-1699.	0.7	19
126	Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD). Frontiers in Aging Neuroscience, 2018, 10, 47.	1.7	13

#	Article	IF	CITATIONS
127	Cognitive and Affective Perspective-Taking: Evidence for Shared and Dissociable Anatomical Substrates. Frontiers in Neurology, 2018, 9, 491.	1.1	118
128	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	3.7	448
129	Longitudinal Changes in Semantic Concreteness in Semantic Variant Primary Progressive Aphasia (svPPA). ENeuro, 2018, 5, ENEURO.0197-18.2018.	0.9	20
130	Differences in Hearing Acuity among "Normal-Hearing―Young Adults Modulate the Neural Basis for Speech Comprehension. ENeuro, 2018, 5, ENEURO.0263-17.2018.	0.9	12
131	Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathologica, 2017, 134, 65-78.	3.9	163
132	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	2.2	121
133	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	2.2	1,402
134	Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. Neurology, 2017, 88, 2276-2284.	1.5	114
135	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. Brain and Language, 2017, 171, 42-51.	0.8	43
136	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp><i>C9ORF</i></scp> <i>72</i> â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	2.8	88
137	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	0.9	98
138	Poly(GP) proteins are a useful pharmacodynamic marker for <i>C9ORF72</i> -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	5.8	179
139	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	4.9	394
140	Dissociable substrates underlie the production of abstract and concrete nouns. Brain and Language, 2017, 165, 45-54.	0.8	28
141	¹⁸ Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	2.8	148
142	[P2–317]: PHENOCONVERSION FROM ASYMPTOMATIC TO MINIMALLY SYMPTOMATIC FTLD: PRELIMINARY DATA IN THE LEFFTDS COHORT. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
143	Evidence of semantic processing impairments in behavioural variant frontotemporal dementia and Parkinson's disease. Current Opinion in Neurology, 2017, 30, 617-622.	1.8	12
144	Optical coherence tomography identifies outer retina thinning in frontotemporal degeneration. Neurology, 2017, 89, 1604-1611.	1.5	39

#	Article	IF	CITATIONS
145	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	2.8	51
146	Automatic measurement of prosody in behavioral variant FTD. Neurology, 2017, 89, 650-656.	1.5	46
147	Brain network efficiency is influenced by the pathologic source of corticobasal syndrome. Neurology, 2017, 89, 1373-1381.	1.5	27
148	[P4â€"189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.4	2
149	Category learning in Alzheimer's disease and normal cognitive aging depends on initial experience of feature variability. Neuropsychologia, 2017, 98, 98-110.	0.7	2
150	[P4–238]: AMNESTIC AND NONâ€AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE: AN MRIâ€BASED PHASIN ANALYSIS. Alzheimer's and Dementia, 2017, 13, P1365.	IG 0.4	0
151	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer's Research and Therapy, 2017, 9, 89.	3.0	129
152	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. Frontiers in Human Neuroscience, 2017, 10, 693.	1.0	1
153	Semantic Feature Training in Combination with Transcranial Direct Current Stimulation (tDCS) for Progressive Anomia. Frontiers in Human Neuroscience, 2017, 11, 253.	1.0	38
154	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. Frontiers in Neuroscience, 2017, 11, 53.	1.4	7
155	Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration. Acta Neuropathologica Communications, 2017, 5, 68.	2.4	34
156	The Two Sides of Sensory–Cognitive Interactions: Effects of Age, Hearing Acuity, and Working Memory Span on Sentence Comprehension. Frontiers in Psychology, 2016, 7, 236.	1.1	38
157	Arterial spin labeling perfusion predicts longitudinal decline in semantic variant primary progressive aphasia. Journal of Neurology, 2016, 263, 1927-1938.	1.8	23
158	Deep clinical and neuropathological phenotyping of <scp>P</scp> ick disease. Annals of Neurology, 2016, 79, 272-287.	2.8	146
159	Causal Evidence for a Mechanism of Semantic Integration in the Angular Gyrus as Revealed by High-Definition Transcranial Direct Current Stimulation. Journal of Neuroscience, 2016, 36, 3829-3838.	1.7	108
160	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism and Related Disorders, 2016, 28, 41-48.	1.1	33
161	Using precise word timing information improves decoding accuracy in a multiband-accelerated multimodal reading experiment. Cognitive Neuropsychology, 2016, 33, 265-275.	0.4	18
162	Cognitive reserve in frontotemporal degeneration. Neurology, 2016, 87, 1813-1819.	1.5	40

#	Article	IF	CITATIONS
163	A race effect on amyloid deposition?. Neurology, 2016, 87, 454-455.	1.5	0
164	Dissociation of quantifiers and object nouns in speech in focal neurodegenerative disease. Neuropsychologia, 2016, 89, 141-152.	0.7	21
165	Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome. Neurology, 2016, 87, 1227-1234.	1.5	25
166	Transcranial direct current stimulation for the treatment of primary progressive aphasia: An open-label pilot study. Brain and Language, 2016, 162, 35-41.	0.8	50
167	Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration. Acta Neuropathologica, 2016, 132, 935-937.	3.9	81
168	Dementia overview. , 2016, , 132-139.		0
169	Computerized assessment of goal-directed behavior in Parkinson's disease. Journal of Clinical and Experimental Neuropsychology, 2016, 38, 1015-1025.	0.8	5
170	Semi-Automated Digital Image Analysis of Pick's Disease and TDP-43 Proteinopathy. Journal of Histochemistry and Cytochemistry, 2016, 64, 54-66.	1.3	43
171	Acoustic richness modulates the neural networks supporting intelligible speech processing. Hearing Research, 2016, 333, 108-117.	0.9	25
172	Cognitive and anatomic double dissociation in the representation of concrete and abstract words in semantic variant and behavioral variant frontotemporal degeneration. Neuropsychologia, 2016, 84, 244-251.	0.7	48
173	Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathologica, 2016, 131, 393-409.	3.9	123
174	Semantics of the Visual Environment Encoded in Parahippocampal Cortex. Journal of Cognitive Neuroscience, 2016, 28, 361-378.	1.1	31
175	Social Coordination in Older Adulthood: A Dual-Process Model. Experimental Aging Research, 2016, 42, 112-127.	0.6	11
176	How the brain learns how few are "many― An fMRI study of the flexibility of quantifier semantics. NeuroImage, 2016, 125, 45-52.	2.1	5
177	Resting State Brain Entropy Alterations in Relapsing Remitting Multiple Sclerosis. PLoS ONE, 2016, 11, e0146080.	1.1	45
178	Estimating frontal and parietal involvement in cognitive estimation: a study of focal neurodegenerative diseases. Frontiers in Human Neuroscience, 2015, 9, 317.	1.0	19
179	Processing ambiguity in a linguistic context: decision-making difficulties in non-aphasic patients with behavioral variant frontotemporal degeneration. Frontiers in Human Neuroscience, 2015, 9, 583.	1.0	4
180	Apathy in Frontotemporal Degeneration: Neuroanatomical Evidence of Impaired Goal-directed Behavior. Frontiers in Human Neuroscience, 2015, 9, 611.	1.0	57

#	Article	IF	CITATIONS
181	<i>C9orf72</i> promoter hypermethylation is neuroprotective. Neurology, 2015, 84, 1622-1630.	1.5	66
182	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	3.9	65
183	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathologica, 2015, 129, 469-491.	3.9	218
184	Getting on the same page: The neural basis for social coordination deficits in behavioral variant frontotemporal degeneration. Neuropsychologia, 2015, 69, 56-66.	0.7	26
185	Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science, 2015, 347, 1436-1441.	6.0	823
186	Deficits in sentence expression in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 31-39.	1.1	51
187	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
188	A Meta-analysis of Transcranial Direct Current Stimulation Studies Examining the Reliability of Effects on Language Measures. Brain Stimulation, 2015, 8, 1093-1100.	0.7	82
189	Beyond words: Pragmatic inference in behavioral variant of frontotemporal degeneration. Neuropsychologia, 2015, 75, 556-564.	0.7	12
190	Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration. Neurology, 2015, 84, 2070-2075.	1.5	30
191	Defects of mutant DNMT1 are linked to a spectrum of neurological disorders. Brain, 2015, 138, 845-861.	3.7	94
192	Impaired Cognitive Flexibility in Amyotrophic Lateral Sclerosis. Cognitive and Behavioral Neurology, 2015, 28, 17-26.	0.5	22
193	Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 339-348.	1.2	35
194	Integrated multimodal imaging in neurodegenerative disease. Lancet Neurology, The, 2015, 14, 973-975.	4.9	3
195	The relative contributions of frontal and parietal cortex for generalized quantifier comprehension. Frontiers in Human Neuroscience, 2014, 8, 610.	1.0	10
196	Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia. Neurology, 2014, 83, 502-509.	1.5	26
197	Biomarkers in the primary progressive aphasias. Aphasiology, 2014, 28, 922-940.	1.4	17
198	Narrative discourse deficits in amyotrophic lateral sclerosis. Neurology, 2014, 83, 520-528.	1.5	40

#	Article	IF	CITATIONS
199	Grammatical comprehension deficits in non-fluent/agrammatic primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 249-256.	0.9	46
200	Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 442.	4.5	74
201	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathologica, 2014, 127, 423-439.	3.9	237
202	Sparse canonical correlation analysis relates network-level atrophy to multivariate cognitive measures in a neurodegenerative population. NeuroImage, 2014, 84, 698-711.	2.1	73
203	Corticobasal syndrome. Neurology: Clinical Practice, 2014, 4, 304-312.	0.8	36
204	ALS-Plus syndrome: Non-pyramidal features in a large ALS cohort. Journal of the Neurological Sciences, 2014, 345, 118-124.	0.3	51
205	Counting or chunking? Mathematical and heuristic abilities in patients with corticobasal syndrome and posterior cortical atrophy. Neuropsychologia, 2014, 64, 176-183.	0.7	13
206	Action verb comprehension in amyotrophic lateral sclerosis and Parkinson's disease. Journal of Neurology, 2014, 261, 1073-1079.	1.8	42
207	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
208	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.4	167
209	Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration. Neurobiology of Aging, 2014, 35, 1473-1482.	1.5	43
210	Relating brain anatomy and cognitive ability using a multivariate multimodal framework. NeuroImage, 2014, 99, 477-486.	2.1	29
211	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurology, The, 2014, 13, 676-685.	4.9	245
212	Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry. Journal of Alzheimer's Disease, 2014, 41, 441-451.	1.2	94
213	Development and Validation of Pedigree Classification Criteria for Frontotemporal Lobar Degeneration. JAMA Neurology, 2013, 70, 1411.	4.5	107
214	Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. Brain and Language, 2013, 127, 106-120.	0.8	77
215	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.5	1,445
216	Category-specific semantic memory: Converging evidence from bold fMRI and Alzheimer's disease. NeuroImage, 2013, 68, 263-274.	2.1	30

#	Article	IF	CITATIONS
217	Stages of pTDPâ€43 pathology in amyotrophic lateral sclerosis. Annals of Neurology, 2013, 74, 20-38.	2.8	820
218	White Matter Disease Correlates with Lexical Retrieval Deficits in Primary Progressive Aphasia. Frontiers in Neurology, 2013, 4, 212.	1.1	29
219	Differential Longitudinal Decline on the Mini-Mental State Examination in Frontotemporal Lobar Degeneration and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 310-315.	0.6	26
220	Differentiating primary progressive aphasias in a brief sample of connected speech. Neurology, 2013, 81, 329-336.	1.5	126
221	Cognitive decline and reduced survival in <i>C9orf72</i> expansion frontotemporal degeneration and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 163-169.	0.9	141
222	Behavior Matters—Cognitive Predictors of Survival in Amyotrophic Lateral Sclerosis. PLoS ONE, 2013, 8, e57584.	1.1	61
223	The neural basis for establishing a focal point in pure coordination games. Social Cognitive and Affective Neuroscience, 2012, 7, 881-887.	1.5	20
224	Deficits in concept formation in amyotrophic lateral sclerosis Neuropsychology, 2012, 26, 422-429.	1.0	38
225	Multimodal Comparative Studies of Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2012, 33, S379-S383.	1.2	2
226	The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurology, The, 2012, 11, 545-555.	4.9	188
227	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	3.9	161
228	Difficulty processing temporary syntactic ambiguities in Lewy body spectrum disorder. Brain and Language, 2012, 120, 52-60.	0.8	23
229	Impairments of speech fluency in Lewy body spectrum disorder. Brain and Language, 2012, 120, 290-302.	0.8	47
230	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathologica, 2012, 123, 395-407.	3.9	104
231	Apathy in Frontotemporal Dementia: Behavioral and Neuroimaging Correlates. Behavioural Neurology, 2012, 25, 127-136.	1.1	89
232	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
233	Building an integrated neurodegenerative disease database at an academic health center. Alzheimer's and Dementia, 2011, 7, e84-93.	0.4	63
234	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica, 2011, 121, 373-380.	3.9	102

#	Article	IF	CITATIONS
235	Biomarkers to Identify the Pathological Basis for Frontotemporal Lobar Degeneration. Journal of Molecular Neuroscience, 2011, 45, 366-371.	1.1	5
236	The Philadelphia Brief Assessment of Cognition (PBAC): A Validated Screening Measure for Dementia. Clinical Neuropsychologist, 2011, 25, 1314-1330.	1.5	46
237	Social Cognition, Executive Functioning, and Neuroimaging Correlates of Empathic Deficits in Frontotemporal Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 74-82.	0.9	150
238	Biomarkers in frontotemporal lobar degeneration. Current Opinion in Neurology, 2010, 23, 643-648.	1.8	15
239	The role of ventral medial prefrontal cortex in social decisions: Converging evidence from fMRI and frontotemporal lobar degeneration. Neuropsychologia, 2010, 48, 3505-3512.	0.7	67
240	Speech errors in progressive non-fluent aphasia. Brain and Language, 2010, 113, 13-20.	0.8	104
241	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
242	Hierarchical Organization of Scripts: Converging Evidence from fMRI and Frontotemporal Degeneration. Cerebral Cortex, 2010, 20, 2453-2463.	1.6	40
243	Primary progressive aphasia: clinicopathological correlations. Nature Reviews Neurology, 2010, 6, 88-97.	4.9	347
244	Dementia induces correlated reductions in white matter integrity and cortical thickness: A multivariate neuroimaging study with sparse canonical correlation analysis. NeuroImage, 2010, 50, 1004-1016.	2.1	163
245	Reversal of the concreteness effect in semantic dementia. Cognitive Neuropsychology, 2009, 26, 568-579.	0.4	103
246	Neuroanatomy of Apathy and Disinhibition in Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2009, 27, 96-104.	0.7	140
247	Non-fluent speech in frontotemporal lobar degeneration. Journal of Neurolinguistics, 2009, 22, 370-383.	0.5	119
248	Registration based cortical thickness measurement. Neurolmage, 2009, 45, 867-879.	2.1	217
249	Longitudinal Cortical Atrophy in Amyotrophic Lateral Sclerosis With Frontotemporal Dementia. Archives of Neurology, 2009, 66, 138-9.	4.9	17
250	Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease. Archives of Neurology, 2009, 66, 1359-64.	4.9	83
251	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurology, The, 2008, 7, 409-416.	4.9	636
252	Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2008, 173, 182-194.	1.9	284

#	Article	IF	CITATIONS
253	Narrative speech production: An fMRI study using continuous arterial spin labeling. NeuroImage, 2008, 40, 932-939.	2.1	63
254	TDP-43 Pathologic Lesions and Clinical Phenotype in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. Archives of Neurology, 2007, 64, 1449.	4.9	61
255	Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia. Archives of Neurology, 2007, 64, 1601.	4.9	91
256	Screening for Frontotemporal Dementias and Alzheimer's Disease with the Philadelphia Brief Assessment of Cognition: A Preliminary Analysis. Dementia and Geriatric Cognitive Disorders, 2007, 24, 441-447.	0.7	39
257	Process and content in semantic memory. , 2007, , 247-264.		15
258	Measuring Cortical Thickness Using An Image Domain Local Surface Model And Topology Preserving Segmentation. , 2007, , .		0
259	Neuropsychiatric features of Amyotrophic Lateral Sclerosis. NeuroRehabilitation, 2007, 22, 425-429.	0.5	3
260	How necessary are the stripes of a tiger?. Neuropsychologia, 2007, 45, 1055-1064.	0.7	11
261	Verb acquisition and representation in Alzheimer's disease. Neuropsychologia, 2007, 45, 2508-2518.	0.7	36
262	Number sense and quantifier interpretation. Topoi, 2007, 26, 51-62.	0.8	32
263	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science, 2006, 314, 130-133.	6.0	5,422
264	Category-specific effects in semantic memory: Category–task interactions suggested by fMRI. NeuroImage, 2006, 30, 1003-1009.	2.1	12
265	Understanding diversity: A multimodal approach to good and poor aphasia therapy outcomes. Journal of the International Neuropsychological Society, 2006, 12, 130-131.	1.2	Ο
266	Oops! Resolving social dilemmas in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 457-460.	0.9	123
267	Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2005, 19, S1-S2.	0.6	Ο
268	Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Annals of Neurology, 2005, 57, 721-729.	2.8	217
269	Sentence Processing in Frontotemporal Dementia. Cortex, 2005, 41, 764-777.	1.1	67
270	Verbal learning in semantic dementia: Is repetition priming a useful strategy?. Aphasiology, 2005, 19, 329-339.	1.4	34

#	Article	IF	CITATIONS
271	Primary Progressive Aphasia: A Review. Neurocase, 2004, 10, 3-18.	0.2	152
272	Categorization of object descriptions in Alzheimer's disease and frontotemporal dementia: Limitation in rule-based processing. Cognitive, Affective and Behavioral Neuroscience, 2003, 3, 120-132.	1.0	26
273	What's in a name: voxel-based morphometric analyses of MRI and naming difficulty in Alzheimer's disease, frontotemporal dementia and corticobasal degeneration. Brain, 2003, 127, 628-649.	3.7	318
274	Neural basis for semantic memory difficulty in Alzheimer's disease: an fMRI study. Brain, 2003, 126, 292-311.	3.7	128
275	Neural Basis for Verb Processing in Alzheimer's Disease: An fMRI Study Neuropsychology, 2003, 17, 658-674.	1.0	53
276	Frontotemporal dementia: A review. Journal of the International Neuropsychological Society, 2002, 8, 566-583.	1.2	158
277	Progressive aphasic syndromes: clinical and theoretical advances. Current Opinion in Neurology, 2002, 15, 409-413.	1.8	28
278	Sentence Processing Strategies in Healthy Seniors with Poor Comprehension: An fMRI Study. Brain and Language, 2002, 80, 296-313.	0.8	58
279	Assessing Resource Demands during Sentence Processing in Parkinson's Disease. Brain and Language, 2002, 80, 603-616.	0.8	85
280	Age-Related Changes in Working Memory during Sentence Comprehension: An fMRI Study. NeuroImage, 2002, 15, 302-317.	2.1	160
281	The Neural Basis for Category-Specific Knowledge: An fMRI Study. NeuroImage, 2002, 15, 936-948.	2.1	117
282	The Neural Basis for Categorization in Semantic Memory. NeuroImage, 2002, 17, 1549-1561.	2.1	143
283	Neural representation of verb meaning: An fMRI study. Human Brain Mapping, 2002, 15, 124-134.	1.9	99
284	Information processing speed and sentence comprehension in Parkinson's disease. Neuropsychology, 2002, 16, 174-81.	1.0	39
285	A Theory of the Neural Basis for Language Functioning. Journal of the International Neuropsychological Society, 2001, 7, 778-778.	1.2	0
286	Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. Annals of Neurology, 2001, 49, 165-175.	2.8	159
287	Verb Comprehension in Frontotemporal Degeneration: The Role of Grammatical, Semantic and Executive Components Neurocase, 2001, 7, 173-184.	0.2	80
288	Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Annals of Neurology, 2000, 47, 93-100.	2.8	381

#	Article	IF	CITATIONS
289	Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. , 2000, 47, 93.		1
290	Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease. Annals of Neurology, 1998, 43, 259-265.	2.8	55
291	Freehand drawing impairments in probable Alzheimer's disease. Journal of the International Neuropsychological Society, 1996, 2, 226-235.	1.2	9
292	Progressive Nonfluent Aphasia: Language, Cognitive, and PET Measures Contrasted with Probable Alzheimer's Disease. Journal of Cognitive Neuroscience, 1996, 8, 135-154.	1.1	204
293	The neural basis of the central executive system of working memory. Nature, 1995, 378, 279-281.	13.7	1,397
294	Comprehension of Lexical Subcategory Distinctions by Aphasic Patients. Journal of Speech, Language, and Hearing Research, 1989, 32, 481-488.	0.7	14
295	Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer's Disease Pathology and Associated with Cognitive and Functional Decline. SSRN Electronic Journal, O. , .	0.4	6